# Neurocrine Biosciences Inc (NBIX)

> Neurocrine Biosciences Inc (NBIX) trades at $164.96 (+3.25%) as of 1:43:39 PM EST on Nov 6, 2026, +17.12% over the past month. Market cap is $16.17B, with 4.5 days to cover in short interest.

Canonical: https://massive.com/quote/nbix
Data as of: 2026-11-06T18:43:39.796Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$164.96** +5.20 (+3.25%)
As of 1:43:39 PM EST on Nov 6, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Neurocrine Biosciences Inc (NBIX) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +3.55% |
| 1W | +13.23% |
| 1M | +17.12% |
| YTD | +16.64% |
| 1Y | +8.57% |
| 52-wk range | $122.14 – $186.12 |

From daily closes through Nov 6, 2026.

## Key statistics

Today's trading snapshot for NBIX: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $158.66 – $165.86 |
| Open | $159.98 |
| Prev close | $159.76 |
| Volume | 768.72K |
| Market cap | $16.17B |
| Shares out | 101.65M |

## Valuation and profitability ratios

Valuation and profitability ratios for Neurocrine Biosciences Inc: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | 23.02 |
| P/S | 4.37 |
| P/B | 4.17 |
| P/FCF | 15.55 |
| ROE | 18.1% |
| ROA | 12.5% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 5, 2026

## Insider trading

[Neurocrine Biosciences Inc (NBIX) insider trading](https://massive.com/quote/nbix/insider-trading.md): open-market Form 4 buys and sells by Neurocrine Biosciences Inc insiders over the last 12 months.

## 8-K filings

Material corporate events Neurocrine Biosciences Inc has disclosed to the SEC on Form 8-K.

- Nov 2, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 2, 2026, Neurocrine Biosciences, Inc. announced its financial results for the third quarter ended September 30, 2026.”
- Sep 28, 2026 · Executive officer appointment
  “On September 28, 2026, the Board of Directors ... appointed Eiry W. Roberts, M.D., to succeed Sanjay Keswani, M.D., as the Company's Chief Medical Officer, effective September 28, 2026.”
- May 18, 2026 · [Merger completion](https://massive.com/quote/sec-filings/8-k/mergers.md)
  “The Company completed the acquisition of Soleno on May 18, 2026, by causing Purchaser to merge with and into Soleno (the "Merger") pursuant to the Merger Agreement without any action by Soleno stockholders in accordance with Section 251(h) of the General Corporation Law of the State of Delaware (the "DGCL"). At the effective time of the Merger (the "Effective Time"), Purchaser was merged with and into Soleno, the separate existence of Purchaser ceased and Soleno continued as a direct wholly owned subsidiary of the Company.”
- Apr 6, 2026 · Investor presentation
  “On April 6, 2026, Neurocrine made available an investor presentation regarding the proposed transaction, a copy of which is attached as Exhibit 99.2 to this Report and incorporated by reference herein.”
- Nov 24, 2025 · [Executive officer departure](https://massive.com/quote/sec-filings/8-k/executive-departures.md)
  “Sanjay Keswani, M.D. succeeded Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (the "Company"), effective June 2, 2025.”

## NBIX short interest

How heavily NBIX is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.5 |
| Short interest | 6.45M |
| Avg volume | 1.42M |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## NBIX news

The latest news and headlines about Neurocrine Biosciences Inc (NBIX).

- [NBIX Beats on Q3 Earnings & Sales, Raises '26 Ingrezza Sales View](https://www.zacks.com/stock/news/3021962/nbix-beats-on-q3-earnings-sales-raises-26-ingrezza-sales-view?cid=CS-ZC-FT-analyst_blog|earnings_article-3021962) · Zacks Investment Research · Nov 3, 2026 · positive sentiment
- [Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates](https://www.zacks.com/stock/news/3021247/neurocrine-biosciences-nbix-q3-earnings-and-revenues-top-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3021247) · Zacks Investment Research · Nov 2, 2026 · neutral sentiment
- [Neurocrine (NBIX) Reports Q3 Earnings: What Key Metrics Have to Say](https://www.zacks.com/stock/news/3021228/neurocrine-nbix-reports-q3-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-3021228) · Zacks Investment Research · Nov 2, 2026 · positive sentiment
- [Here's Why Neurocrine Biosciences (NBIX) is a Strong Growth Stock](https://www.zacks.com/stock/news/3019614/here-s-why-neurocrine-biosciences-nbix-is-a-strong-growth-stock?cid=CS-ZC-FT-fundamental_analysis|zacks_education_growth_score-3019614) · Zacks Investment Research · Oct 30, 2026 · positive sentiment
- [Amneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?](https://www.zacks.com/stock/news/3016028/amneal-pharmaceuticals-amrx-earnings-expected-to-grow-should-you-buy?cid=CS-ZC-FT-fundamental_analysis|yseop_template_9-3016028) · Zacks Investment Research · Oct 27, 2026 · positive sentiment

## About Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 2.5K |
| Listed | May 23, 1996 |

[Company website](https://www.neurocrine.com)

## FAQ

### What is the Neurocrine Biosciences Inc (NBIX) stock price today?

Neurocrine Biosciences Inc (NBIX) is trading at $164.96 (+3.25% on the day) as of 1:43:39 PM EST on Nov 6, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Neurocrine Biosciences Inc?

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders.

### What is the short interest in NBIX?

As of Oct 15, 2026, NBIX has 6.45M shares short and 4.5 days to cover.

### What exchange is NBIX listed on?

Neurocrine Biosciences Inc (NBIX) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time NBIX quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=NBIX`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Neurocrine Biosciences Inc (NBIX) insider trading](https://massive.com/quote/nbix/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms